Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Total Liabilities of $196.4 million for Q1 2026, up 7.89% year-over-year from $182.0 million in Q1 2025, and down 7.16% quarter-over-quarter from $211.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Total Liabilities data on file, last reported at $196.4 million in Q1 2026.
- Total Liabilities for Q1 2026 came in at $196.4 million, up 7.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $196.4 million (up 7.89% YoY), and the FY2025 annual result was $211.5 million, up 6.19% from the prior year.
- Total Liabilities fell to $196.4 million in Q1 2026 per AMRN's latest filing, from $211.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $393.2 million in Q2 2022 and troughed at $182.0 million in Q1 2025.
- A 5-year average of $257.4 million and a median of $248.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities declined 28.76% in 2024, then grew 7.89% in 2026.
- A 5-year view of Total Liabilities shows it stood at $290.8 million in 2022, then decreased by 3.87% to $279.6 million in 2023, then decreased by 28.76% to $199.2 million in 2024, then grew by 6.19% to $211.5 million in 2025, then declined by 7.16% to $196.4 million in 2026.
- Business Quant data shows AMRN's Total Liabilities at $196.4 million in Q1 2026, $211.5 million in Q4 2025, and $200.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -61.27 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 85.38 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.71 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 143.08 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 82.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 66.37 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 196.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.35 Mn |
| Dec 31, 2025 | 211.49 Mn |
| Sep 30, 2025 | 200.92 Mn |
| Jun 30, 2025 | 205.20 Mn |
| Mar 31, 2025 | 181.99 Mn |
| Dec 31, 2024 | 199.17 Mn |
| Sep 30, 2024 | 219.24 Mn |
| Jun 30, 2024 | 247.98 Mn |
| Mar 31, 2024 | 244.08 Mn |
| Dec 31, 2023 | 279.59 Mn |
| Sep 30, 2023 | 285.88 Mn |
| Jun 30, 2023 | 290.89 Mn |
| Mar 31, 2023 | 275.40 Mn |
| Dec 31, 2022 | 290.85 Mn |
| Sep 30, 2022 | 320.48 Mn |
| Jun 30, 2022 | 393.19 Mn |
| Mar 31, 2022 | 332.60 Mn |
| Dec 31, 2021 | 400.97 Mn |
| Sep 30, 2021 | 393.31 Mn |
| Jun 30, 2021 | 399.67 Mn |